Articles. Funding The Danish Council for Strategic Research and Aarhus University.
|
|
- Dominic Dean
- 5 years ago
- Views:
Transcription
1 Panobinostat, a histone deacetylase inhibitor, for latentvirus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial Thomas A Rasmussen, Martin Tolstrup, Christel R Brinkmann, Rikke Olesen, Christian Erikstrup, Ajantha Solomon, Anni Winckelmann, Sarah Palmer, Charles Dinarello, Maria Buzon, Mathias Lichterfeld, Sharon R Lewin, Lars Østergaard, Ole S Søgaard Summary Background Activating the expression of latent virus is an approach that might form part of an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to disrupt HIV-1 latency and the safety of this strategy. Methods In this phase 1/2 clinical trial, we included aviraemic adults with HIV treated at Aarhus University Hospital, Denmark. Participants received oral panobinostat (2 mg) three times per week every other week for 8 weeks while maintaining combination antiretroviral therapy. The primary outcome was change from baseline of cell-associated unspliced HIV RNA. Secondary endpoints were safety, plasma HIV RNA, total and integrated HIV DNA, infectious units per million CD4 T cells, and time to viral rebound during an optional analytical treatment interruption of antiretroviral therapy. This trial is registered with ClinicalTrial.gov, number NCT Findings We enrolled 15 patients. The level of cell-associated unspliced HIV RNA increased significantly at all timepoints when patients were taking panobinostat (p< 1). The median maximum increase in cell-associated unspliced HIV RNA during panobinostat treatment was 3 5-fold (range ). Panobinostat induced plasma viraemia with an odds ratio of 1 5 (95% CI ; p= 2) compared with baseline. We recorded a transient decrease in total HIV DNA, but no cohort-wide reduction in total HIV DNA, integrated HIV DNA, or infectious units per million. Nine patients participated in the analytical treatment interruption, median time to viral rebound was 17 days (range 14 56). Panobinostat was well tolerated. 45 adverse events were reported, but only 16 (all grade 1) were presumed related to panobinostat. Interpretation Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication. However, panobinostat did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir. Funding The Danish Council for Strategic Research and Aarhus University. Introduction Combination antiretroviral therapy effectively suppresses replication of HIV but persisting virus fuels rebound viraemia when treatment ceases. 1 Thus, lifelong adherence to antiretroviral therapy is necessary for disease control, raising concerns of long-term adverse effects and the financial burden of treatment. The development of treatments that cure infection, therefore, is a fundamental goal in HIV research. The most significant obstacle to eradication of HIV infection is the presence of replication-competent provirus in long-lived resting CD4 T cells. 2 4 In the transcriptionally silent resting state, viral proteins are not expressed and, therefore, the infected status of resting cells remains invisible to the immune system and unresponsive to antiretroviral therapy. This reversibly non-productive state of infection is referred to as HIV latency. 5 Drugs aimed at activating HIV from latency should ideally induce viral transcription, lead to viral protein production, and release of viral particles essential prerequisites for immune-mediated elimination. 6 However, the effect of this approach is subject to ongoing controversy with an ex-vivo study suggesting that none of the leading candidate drugs can alone disrupt the latent HIV reservoir. 7 Clinical trials are the only experimental approaches to investigate whether drugs aimed at disrupting HIV latency in vivo are effective or not. One of several mechanisms controlling HIV latency is the activity of histone deacetylases, which repress proviral transcription by promoting histone deacetylation. 8,9 Several studies have shown that histone deacetylase inhibitors disrupt HIV latency in vitro Additionally, administration of a single dose of vorinostat a histone deacetylase inhibitor approved by the US Food and Drug Administration led to significant increases in cell-associated HIV RNA, 13 as did multiple doses of vorinostat over 14 days. 14 By contrast, three doses per week of vorinostat over 8 weeks only increased amounts of cell-associated HIV RNA above baseline for three of five participants. 15 Increased plasma viraemia or reduction of the latent HIV reservoir have not been shown in studies of vorinostat. These findings have led researchers to Lancet HIV 214; 1: e13 21 Published Online September 16, S (14)714-1 See Comment page e2 Department of Infectious Diseases (T A Rasmussen MD, M Tolstrup PhD, C R Brinkmann PhD, R Olesen PhD, A Winckelmann, Prof L Østergaard DMSc, O S Søgaard MD), Department of Clinical Immunology (C Erikstrup MD), Aarhus University Hospital, Denmark; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia (A Solomon, Prof S R Lewin PhD); Westmead Millennium Institute for Medical Research, University of Sydney, Westmead, NSW, Australia (S Palmer PhD); Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, CO, USA (Prof C Dinarello MD); Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA (M Buzon PhD, M Lichterfeld MD); Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA (M Buzon, M Lichterfeld); and Centre for Biomedical Research, Burnet Institute, Melbourne, VIC, Australia (S R Lewin) Correspondence to: Dr Thomas A Rasmussen, Aarhus University Hospital, Department of Infectious Diseases, Brendstrupgaardsvej 1, DK-822 Aarhus N, Denmark thomrasm@rm.dk Vol 1 October 214 e13
2 See Online for appendix question the ability of histone deacetylase inhibitors to disrupt latency to the extent that HIV proteins are expressed on the surface of infected cells, thus enabling immune-mediated elimination to occur. 7,16,17 Panobinostat is a highly potent hydroxamic acid panhistone deacetylase inhibitor in clinical development for the treatment of multiple myeloma. 18 Therapeutic concentrations of panobinostat induce viral production in latently infected cells in vitro. 19 On the basis of these data, we designed an interventional study to assess whether 8 weeks of cyclic panobinostat treatment added to antiretroviral therapy would increase HIV transcription, increase plasma viraemia, and affect the latent HIV reservoir. Methods Study design and participants We did a single group, phase 1/2 trial at Aarhus University Hospital, Denmark, between Oct 1, 212 and Jan 16, 214. We enrolled HIV-infected adults taking antiretroviral therapy with virological suppression (<5 copies per ml, at least two measurements per year) for at least 2 years and CD4 counts above 5 cells per μl. Exclusion criteria included co-infection with hepatitis B or C viruses, clinically significant cardiac disease including QTc prolongation, and current use of a protease inhibitor (because of drug interactions). Ethics committee approval was obtained in accordance with the principles of the Declaration of Helsinki. Each patient provided written informed consent before any study procedures. Procedures Patients received oral panobinostat (2 mg) three times per week (on Mondays, Wednesdays, and Fridays) every other week for 8 weeks while maintaining combination antiretroviral treatment. This dose regimen was based on clinical safety and preclinical testing of panobinostat s effect on HIV production in latently infected cells. 19,2 Patients had 13 follow-up visits during panobinostat treatment, at which blood draws were taken, including 2 h and 12 h after receipt of the first dose, and 4 weeks and 24 weeks after completion of panobinostat treatment (appendix p 1). All other samples in the weeks of panobinostat treatment were taken roughly 8 h after a panobinostat dose. At each follow-up visit, we assessed adherence to antiretroviral therapy and panobinostat. We measured plasma concentrations of panobinostat and confirmed compliance with pill counts. Safety was actively assessed at all study visits by recording of all patient-reported adverse events and serious adverse events. For each adverse event, we assessed its relation to panobinostat treatment and graded its severity according to the Common Terminology Criteria for Adverse Events (version 4.). 21 We assessed the presence of HIV RNA in plasma by nucleic acid testing with a transcription-mediated amplification detection method (Procleix Ultrio Plus, Novartis). 22 The results were defined as positive or negative. Patients had the option of analytical treatment interruption of antiretroviral therapy after completion of panobinostat treatment and analysis of the primary Sex Ethnic origin Age (years) Months since HIV diagnosis Days from HIV diagnosis to ART initiation ART regimen Months on ART Months with HIV RNA <5 copies per ml Nadir CD4 count (cells per μl) Baseline CD4 count (cells per μl) HLA class 1 A-alleles HLA class 1 B-alleles 1 Man White TDF, FTC, RPV :1:1:1 8:1:57:1 Yes 2 Man White TDF, FTC, RPV :1:24:2 7:2:35:1 Yes 4 Man White TDF, FTC, RAL :1:2:1 8:1:15:1 Yes 5 Man White TDF, FTC, EFV :1:68:1 8:1:35:1 No 6 Man White TDF, FTC, RPV :1:11:1 27:5:4:1 No 7 Man White TDF, FTC, RAL :1:11:1 8:1:35:1 No 8 Man White TDF, FTC, EFV :1:68:1 8:1:4:1 Yes 9 Man White TDF, FTC, EFV :1:3:1 13:2:35:1 Yes 1 Man White TDF, FTC, EFV 12 9 >24 * :1:11:1 8:1:27:5 Yes 12 Man White TDF, FTC, RPV :1:24:2 39:6:44:2 Yes 14 Man White TDF, FTC, EFV :1:3:1 7:2:44:2 No 15 Man White TDF, FTC, EFV :1:32:1 13:2:35:8 No 17 Man White ABC, 3TC, AZT :1:32:1 14:1:18:1 Yes 18 Man White TDF, FTC, EFV :1:24:2 8:1:15:7 Yes 19 Man White TDF, FTC, EFV :2:3:1 13:2:57:1 No Median (range) 47 (28 53) 81 4 ( ) 54 ( 6574) 43 4 ( ) 38 ( ) 35 (13 71) 935 ( ) ART=antiretroviral therapy. TDF=tenofovir disoproxil fumarate. FTC=emtricitabine. RPV=rilpivirine. RAL=raltegravir. EFV=efavirenz. ABC=abacavir. 3TC=lamivudine. AZT=zidovudine. ATI=analytical treatment interruption. *Exact value not available, the patient had been away, returning to Norway in 21. Table 1: Participant characteristics ATI? e14 Vol 1 October 214
3 outcome. Declining to participate in the interruption at study enrolment did not preclude participation in the study. During the analytical treatment interruption, patients were monitored for viral load (twice weekly; Cobas Taqman, quantification limit 19 copies per ml) and CD4 cell counts (weekly). Two consecutive viral load measurements of more than 1 copies per ml or CD4 count of less than 35 cells per μl prompted resumption of antiretroviral therapy. Because withdrawal of anti retroviral therapy is considered the ultimate test of an intervention targeting the latent HIV reservoir, 23 we explored possible correlations between the time to viral rebound during analytical treatment interruption and changes in HIV DNA and viral outgrowth assay estimates of infectious units per million in post-hoc analyses. The appendix shows detailed methods. Endpoints The primary outcome measure was change from baseline of HIV transcription as measured by cell-associated unspliced HIV RNA in unfractionated CD4 cells. Secondary endpoints were incidence and severity of adverse events, change from baseline of plasma HIV RNA concentration, change from baseline of total and integrated proviral HIV DNA per 1⁶ CD4 cells, change from baseline in the proportion of cells carrying replication-competent virus as assessed by a viral outgrowth assay, and time to first viral load of more than 1 copies per ml during the optional analytical treatment interruption. The degree of histone acetylation and two-long terminal repeat circles per 1⁶ CD4 cells were prespecified exploratory endpoints. Role of the funding source The funders had no role in study design, data collection, data analysis, data interpretation, writing the article, or in the decision to submit the paper for publication. The Cell-associated unspliced HIV RNA (fold increase) Plasma panobinostat concentration (nmol/l) A B Panobinostat 2 mg treatment Statistical analysis We designed the study to detect a 5 log increase in cellassociated unspliced HIV RNA with 9% power at a 5% significance level. Assuming a standard deviation of 5 log, 24 we required 11 fully evaluable patients. To account for study withdrawals, we aimed to enrol up to 16 patients. We used repeated ANOVA statistics to assess whether longitudinal changes in numerical outcome measures were overall significantly different from baseline. We tested changes from baseline to specific timepoints with paired t tests or Wilcoxon signed-rank tests depending on the distribution of the data. We analysed binary outcomes with a logistic model with a random effect for each patient to allow for correlations caused by repeated observations. On the log-odds scale, we assumed that the random effects had a normal distribution with mean zero and unknown variance. We included baseline versus on-panobinostat as a fixed, dichotomous explanatory variable to estimate the effect of panobinostat (appendix p 11). We used Spearman s rank correlation to explore correlations in post-hoc analyses. This trial is registered with ClinicalTrial.gov, number NCT Histone H3 acetylation (MFI) C Figure 1: Panobinostat treatment and HIV transcription and histone H3 acetylation (A) Mean fold increase from baseline of the level of cell-associated unspliced HIV RNA. (B) Mean panobinostat concentration in plasma. (C) Mean histone H3 acetylation measured by flow cytometry in lymphocytes. Shaded box shows the panobinostat treatment period. Bars are 95% CIs. MFI=mean fluorescence intensity. Vol 1 October 214 e15
4 A Baseline (n=3) 7% 3% On-panobinostat (n=168) 46% 54% Positive Negative HIV RNA positive (%) B Panobinostat 2 mg treatment HIV RNA positive (%) C /21 6/18 7/15 8/23 1/14 13/18 Cell-associated unspliced HIV RNA (copies per million 18S) 12/13 12/ >15 Cell-associated unspliced HIV RNA (copies per 1⁶ 18S) D Ratio 4 3 ( ); p< 1 Negative Positive Result of transcription-mediated amplification assay Figure 2: Panobinostat treatment and HIV plasma viraemia Proportion of positive and negative plasma samples at baseline and on panobinostat (A; the two baseline points are grouped together), and the proportion of positive plasma samples throughout the study (B), according to transcription-mediated amplification; the shaded box shows the panobinostat treatment period. (C) HIV RNA positive plasma sample according to transcription-mediated amplification versus amount of cell-associated unspliced HIV RNA. (D) Amount of cell-associated unspliced HIV RNA in transcription-mediated amplification negative versus positive samples. corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Results We enrolled 15 patients and all completed full panobinostat dosing (table 1). The amount of cell-associated unspliced HIV RNA increased during panobinostat treatment (p< 1; repeated measure ment ANOVA incorporating all data from baseline and on panobinostat); with significant increases at all assayed timepoints compared with baseline (figure 1A, appendix p 3). Amounts of cellassociated unspliced HIV RNA increased rapidly, with a mean increase of 2 4-fold (95% CI ; p< 1) measured 2 h after initiating panobinostat. The maximum increase during panobinostat treatment ranged from 2 1-fold to 14 4-fold for the 15 patients, with a median of 3 5-fold. Plasma concentrations of panobinostat increased for all 15 patients with the highest concentrations measured 2 h after dosing (figure 1B), consistent with a T max of roughly 2 h. 25 Accordingly, mean histone H3 acetylation increased rapidly, by 2 5-fold (95% CI ; p< 1) 2 h after the first dose of panobinostat. Overall, panobinostat treatment resulted in substantial cyclic changes in histone H3 acetylation with increased acetylation detected during panobinostat treatment weeks (figure 1C). We measured plasma viraemia to assess whether the increases in cell-associated unspliced HIV RNA induced by panobinostat were primarily caused by long terminal repeat-initiated transcription. Measurement of cellassociated HIV RNA transcripts by primers to gag could be confounded by readthrough genomic transcripts. 7 Therefore, our ability to document increases in plasma viraemia at the same time as increases in cell-associated unspliced HIV RNA was crucial for showing that panobinostat effectively disrupts HIV latency in vivo. 3% of baseline samples and 54% of samples from patients taking panobinostat (range for all study visits during panobinostat) were positive for plasma HIV RNA (figure 2A, 2B). These data include multiple e16 Vol 1 October 214
5 observations of the same participant. A positive test was more likely on treatment than at baseline (odds ratio 1 5, 95% CI ; p= 2). The probability for detectable plasma viraemia increased from 17 4% at baseline to 68 9% during panobinostat treatment for the average patient. Although four of 15 patients tested positive for plasma HIV RNA at all times (including both baseline measurements), nine of 15 patients tested negative at both baseline measurements and then repeatedly positive during panobinostat treatment (appendix p 8). Detection of plasma HIV RNA was strongly associated with the amount of cell-associated unspliced HIV RNA both during panobinostat dosing (figure 2C) and when all trial samples (ie, at baseline, during treatment, and after treatment) were jointly analysed (appendix p 4). HIV RNA-positive plasma samples had a 4 3-fold (95% CI , p< 1) higher concentration of cell-associated unspliced HIV RNA than did HIV RNA-negative samples (figure 2D). When plasma was spiked with increasing amounts of HIV DNA, DNA was not detected by a transcriptionmediated amplification assay (data not shown). We did four separate measures of HIV-infected cells in peripheral blood and incorporated them into the posthoc analyses that followed the analytical treatment interruption. We assessed total HIV DNA, integrated HIV DNA, two long-terminal-repeat circles, and infectious units per million CD4 cells. We recorded a decrease in total HIV DNA from baseline to day 14 (p= 4; figure 3A). However, by day 37, the concentration had returned to that at baseline. Furthermore, integrated HIV DNA (figure 3B) and two long-terminal-repeat circles (data not shown) did not change significantly from baseline. According to viral outgrowth, the proportion of cells carrying replicationcompetent virus did not change between baseline and after panobinostat treatment. Specifically, the mean infectious units per million was 1 22 (95% CI ) at baseline and 1 21 ( ) 4 weeks after completion of panobinostat (figure 3C, appendix p 9). Thus, despite increased HIV transcription and virion production during panobinostat dosing, our peripheral blood analyses did not detect cohort-wide reductions in the latent HIV reservoir. Inclusion in the analytical treatment interruption was dependent on the outcome of the primary endpoint analysis, which became available in November, 213 (36 46 weeks after completion of panobinostat dosing). All 15 patients were eligible and nine decided to participate. The median time after interruption until the plasma viral load reached more than 1 copies per ml was 17 days (IQR ) and seven of nine patients had rebound viraemia (>1 copies per ml) within 21 days (figure 4A, appendix p 5). Rebound to this concentration took the longest for patients 9 and 4 (figure 4A). We investigated whether these participants had distinguishing characteristics at baseline or during panobinostat treatment that correlated with this delayed viral rebound. We detected no correlation between time to viral rebound during analytical treatment interruption and baseline amounts of total or integrated HIV DNA (figure 4B, 4C). However, we recorded significant correlations between the time to viral rebound and the change in both total and integrated HIV DNA during Infectious units per million Integrated HIV DNA (copies per 1⁶ CD4 T cells) Total HIV DNA (copies per 1⁶ CD4 T cells) A 1⁴ 1³ 1² 1¹ B 1⁴ 1³ 1² 1¹ 1⁰ 1 ¹ C Panobinostat 2 mg treatment Baseline p= 4 p= 6 p= 8 Post-panobinostat Figure 3: Effect of panobinostat on the latent HIV reservoir The median (IQR) amounts of total (A) and integrated (B) HIV DNA per 1 6 CD4 cells. The shaded box shows the panobinostat treatment period. (C) Infectious units per million at baseline and 4 weeks after completion of panobinostat treatment (day 84) as assessed by a quantitative viral outgrowth assay. p= 6 p= 8 p= 8 p= 8 Vol 1 October 214 e17
6 Plasma viral load (copies per ml) Time to viral rebound (days) Time to viral rebound (days) A 1⁷ 1⁶ 1⁵ 1⁴ 1³ 1² 1¹ ART interrupted B Log baseline total HIV DNA Log baseline integrated HIV DNA D p= 9 Rho= 3 p= 3 Rho= 9 C E p= 4 Rho= 27 Participant 1 Participant 2 Participant 4 Participant 8 Participant 9 Participant 1 Participant 12 Participant 17 Participant 18 p= 2 Rho= 72 Limit of quantification Log ratio total HIV DNA Log ratio integrated HIV DNA Figure 4: Viral rebound during analytical antiretroviral treatment interruption (A) HIV viral load in plasma after interruption of antiretroviral treatment. Time to viral rebound to more than 5 copies per ml and the baseline log-transformed total (B) and integrated (C) HIV DNA per 1⁶ CD4 cells. Time to viral rebound to more than 5 copies per ml and ratios of baseline to post-panobinostat total (D) and integrated (E) HIV DNA per 1⁶ CD4 cells. panobinostat treatment (figure 4D, 4E, appendix p 6). Four patients with the largest reduction in total HIV DNA during the trial (patients 4, 5, 9, and 12) had similar patterns, with DNA reduction as early as 14 days after starting panobinostat that was sustained throughout the remainder of the study period (67 84% decrease overall; figure 5). Of these four, patients 4, 9, and 12 participated in the analytical treatment interruption and as a group had a significantly delayed time to viral rebound compared with the six other participants in the treatment interruption (median 28 days, IQR vs 17 days, 16 18; p= 24). HLA class 1 typing did not show protective alleles (HLA-B571, HLA-B573, HLA-B275) in these three i ndividuals (table 1). 26 Panobinostat was safe and well tolerated. 45 adverse events were reported, but only 16 were presumed related to panobinostat; these occurred in ten patients and were all grade 1 (table 2). Fatigue was the most common drugrelated adverse event. One serious adverse event was recorded during the trial but unrelated to panobinostat (hospital admission for headache before starting study treatment). We recorded minor but reversible changes in leucocyte, neutrophil, monocyte, and thrombocyte counts (appendix p 2). By contrast, CD4 cell counts and total lymphocyte counts were unaffected by panobinostat treatment (appendix p 2). We also repeatedly quantified concentrations of cytomegalovirus DNA (in urine) and Epstein-Barr virus DNA (in blood) during panobinostat treatment, but recorded no evidence of unintended DNA virus reactivation (data not shown). Discussion 8 weeks of cyclic treatment with panobinostat was safe, well tolerated, and effectively increased HIV transcription in patients taking antiretroviral therapy. Furthermore, panobinostat-induced HIV transcription was temporally associated with increased detection of plasma HIV RNA. Viral rebound followed treatment interruption, although the time to rebound varied between individuals. Together, these results provide evidence that panobinostat can effectively activate HIV from latency in vivo and that it should be further investigated as a curative intervention for HIV (panel). Three clinical investigations are related to our study In each of these trials, the histone deacetylase inhibitor vorinostat was assessed, which requires higher concentrations than does panobinostat to achieve in vitro efficacy. 19 In the first trial, a single dose of vorinostat increased cell-associated HIV RNA (by fold; n=8) from baseline. 13 Three distinctions between the vorinostat studies and our study exist. First, patients in the single-dose vorinostat trial were preselected for inclusion on the basis of ex vivo assessments of virus induction. By contrast, we did not preselect patients for the capacity of their cells to respond to panobinostat ex vivo. Second, cell-associated HIV RNA was measured in resting memory CD4 T cells in this vorinostat trial, whereas we report it in unfractionated CD4 T cells. Third, whereas no increase in plasma viraemia was reported with vorinostat, 14,15 we detected a concurrent increase in plasma viraemia and cell-associated unspliced HIV RNA during panobinostat treatment. We assayed this effect with a transcriptionmediated amplification-based assay, which has 5% sensitivity at 3 8 copies per ml and 95% sensitivity at 12 copies per ml. 22 This assay has previously been used in studies of potential cures for HIV. 27 By contrast with the single-copy assay, the transcription-mediated amplification assay is fully automated and certified. Additionally, treatment with another histone deacetylase inhibitor, romidepsin (5 mg/m²), increased e18 Vol 1 October 214
7 concentrations of plasma HIV RNA in patients taking antiretroviral therapy. 28 These increases in plasma viraemia were readily measurable with a routine clinical assay. However, until a full assessment is done of the effects of these drugs on latently infected cells and how they modulate host immune responses, 29 speculation about which histone deacetylase inhibitor is best seems premature. The fundamental rationale for targeting the latent HIV reservoir through disruption of virus latency is that immune-mediated mechanisms or viral cytopathic effects will eliminate latently infected cells induced to express HIV. Nevertheless, we did not record a sustained decrease in the size of the latent HIV reservoir after treatment with panobinostat. This shortcoming could be a result of insufficient immune recognition and killing by cytotoxic CD8 cells, necessitating additional immune enhancement treatment. 17 Also, histone deacetylase inhibitors might induce or intensify dysfunction of T-cell responses. 29 Alternatively, more potent HIV reactivation might be needed to facilitate elimination of latently infected cells. In this regard, investigation of the safety and efficacy of higher doses of panobinostat, which may be dosed as high as 6 mg, 3 is warranted. Despite the lack of a cohort-wide sustained reduction in CD4 cell viral DNA concentrations, we did detect a reduction in HIV DNA in some participants. Because we included an analytical treatment interruption, we were able to show that reductions in HIV DNA, as measured by the ratio of HIV DNA after panobinostat versus baseline, correlated with delayed time to rebound. These investigations were done post-hoc, so they warrant cautious interpretation, but ongoing substudies are focused on identifying the distinguishing characteristics associated with reductions in HIV DNA and could be used to predict outcomes of analytical treatment interruptions in future trials. The main limitation of our study was the lack of a control group. Thus, naturally occurring longitudinal variation could account for the increased plasma viraemia, the increased cell-associated unspliced HIV RNA, and decreased HIV DNA we report. This explanation is unlikely, however, given that all patients had had stably suppressed viraemia for at least 2 years before enrolment. Furthermore, both histone acetylation and cell-associated unspliced HIV RNA concentrations rapidly and concurrently increased on initiation of panobinostat. The repetitive increases during cyclic dosing provide additional evidence that an increase in HIV transcription was caused by panobinostat. A second limitation was that the cell-associated virological measures were done in CD4 T cells, considered the primary reservoir for HIV, but we did not assess activation of HIV from latency specifically in resting memory CD4 cells or other cell types that might also harbour latent proviruses HIV DNA concentration (copies per 1⁶ CD4 T cells) Panobinostat 2 mg treatment Participant 4 Participant 12 Participant 5 Other 11 participants Participant 9 Figure 5: Individual total HIV DNA concentrations Four patients who had large reductions in amount of HIV DNA are shown in individual colours. Any grade Grade 1 Grade 2 Number of patients Not presumed related to panobinostat Headache after lumbar puncture No Lower back ache after lumbar puncture No Fracture (accident) No Skin lesion (accident) No Maxillar sinuitis No Increase in thyroid-stimulating hormone No concentration Influenza-like illness No Polyp found during sigmoidoscopy No Rash No Fungal skin infection No Pharyngitis No Upper respiratory tract infection No Monosymptomatic fever No Headache Yes Diarrhoea No Malaise, arthralgia No Postprandial hypoglycaemia No Emotional stress No Syphilis No Presumed related to panobinostat Fatigue No Rash No Diarrhoea No Nausea No Palpitations (normal cardiac examination) No Stomach ache No Vomiting No Sleeplessness No Table 2: Adverse events Serious adverse event? Vol 1 October 214 e19
8 Panel: Research in context Systematic review We searched PubMed on May 3, 214 with the keywords HIV, HIV latency, HIV reservoir, HIV eradication, HIV cure, and HDAC inhibitors. We reviewed and assessed titles and abstracts for relevance. Although many compounds have been investigated in vitro for their ability to reactivate HIV expression, vorinostat is the only histone deacetylase inhibitor that has been assessed in clinical trials thus far. In these studies, administration of vorinostat increased HIV transcription, but did not increase measures of extracellular HIV RNA, nor did vorinostat affect the latent HIV reservoir. These observations have led researchers to question the ability of histone deacetylase inhibitors to disrupt HIV latency to the extent where HIV proteins are expressed on the surface of infected cells, thus enabling immune-mediated elimination. Interpretation We report the first study to investigate the ability of the highly potent histone deacetylase inhibitor panobinostat to activate HIV from latency in vivo. 8 weeks of cyclic treatment with panobinostat was well tolerated and led to significant increases of HIV transcription in patients taking suppressive antiretroviral therapy. Furthermore, panobinostat-induced HIV transcription increased virion production and plasma viraemia. Taken together, these results provide evidence that panobinostat effectively disrupts HIV latency in vivo. Further clinical development of panobinostat for HIV curative interventions is warranted to optimise the drug s reactivation potential and to explore its effect on the latent HIV reservoir when combined with immune enhancement treatments. Our findings show that cyclic treatment with panobinostat can activate HIV from latency, as shown by significant increases in HIV transcription and increased plasma viraemia. Thus, panobinostat is a promising candidate for inclusion in future combination clinical trials designed to activate and eliminate the latent HIV reservoir. Contributors TAR, MT, LØ, and OSS conceived of and designed the study and developed the study protocol. LØ provided clinical oversight of the study. ML, SRL, SP, and CD contributed to the study concept and design. MT coordinated trial sample processing and laboratory procedures. TAR and OSS enrolled patients in the study and did follow-up. CRB, AS, and SRL analysed the primary endpoint. RO developed the method for and did histone acetylation measurements. MB and ML measured cell-associated HIV DNA and viral outgrowth assay. CE, AW, and SP measured plasma HIV RNA concentrations and did the related analyses. All authors interpreted data. TAR, MT, and OSS wrote the first draft of the article. All authors provided input to the article and approved the final version. Acknowledgments We thank Carsten Schade Larsen, Alex Laursen, and Merete Storgaard for clinical guidance during the study and Henrik Støvring for biostatistical support. Amy Shaw provided technical support and Paul W Denton provided input to the drafting of the report. The study was primarily funded by The Danish Council For Strategic Research, but also received contributions from The Danish AIDS Foundation, The Augustinus Foundation, Frode V Nyegaard Foundation, SSAC Foundation, Aarhus University, Aarhus University Hospital, and the American Fund for AIDS Research. Novartis supplied panobinostat for use in the study. SRL s contribution was supported by an Australian National Health and Medical Research Council project grant 19533, an NHMRC Practitioner Fellowship and the Division of AIDS, National Institute of Allergy and Infectious Disease, US National Institutes of Health (Delaney AIDS Research Enterprise; U19AI9619). We wish to express our sincere gratitude to the study patients for their participation in the study. Declaration of interests Aarhus University has filed a patent application covering the use of panobinostat in HIV-infected patients on which TAR, MT, CRB, LØ and OSS are inventors. SRL has received funding from Merck and Gilead for investigator-initiated research grants and has participated in educational activities for Viiv Healthcare; all payments and honoraria have been paid to her institution. AS, AW, MB, ML, RO, SP, and CE declare no competing interests. References 1 Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96: Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 212; 37: Deeks SG. HIV: shock and kill. Nature 212; 487: Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 214; 2: Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. Embo J 1996; 15: Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p5 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 26; 25: Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 29; 25: Wightman F, Lu HK, Solomon AE, et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 213; 27: Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother 214; 69: Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 212; 487: Elliott JH, Solomon A, Wightman F, et al. The safety and effect of multiple doses of vorinostat on HIV transcription in HIV-infected patients receiving combination antiretroviral therapy. Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, USA; March 3 6, 213. LB5. 15 Archin NM, Bateson R, Tripathy M, et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J Infect Dis 214; 21: Ho YC, Laird GM, Siliciano RF. Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. Proc Natl Acad Sci USA 214; 111: e2 Vol 1 October 214
9 17 Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 212; 36: Xiaoyang L, Jian Z, Yuanchao X, Yuqi J, Zhang Y, Wenfang X. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets 214; 15: Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 213; 9: Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathogens 214; 1: e US Department of Health and Human Services. Common Terminology Criteria for Adverse Events version nih.gov/ftp1/ctcae/ctcae_4.3_ _quickreference_5x7. pdf (accessed Sept 5, 214). 22 Stramer SL, Krysztof DE, Brodsky JP, et al. Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion 213; 53: Eyal N, Kuritzkes DR. Challenges in clinical trial design for HIV-1 cure research. Lancet 213; 382: Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 29; 4: e Anne M, Sammartino D, Barginear MF, Budman D. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther 213; 6: Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity 212; 37: Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 213; 27: Sogaard OS, Graversen ME, Leth S, et al. The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. International AIDS Conference 214. Melbourne, Australia; July 2 25, 214; TUAA16LB. 29 Jones RB, O Connor R, Mueller S, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog 214; 1: e DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 213; 27: Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 29; 66: Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 21; 15: Collman R, Hassan NF, Walker R, et al. Infection of monocytederived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J Exp Med 1989; 17: Vol 1 October 214 e21
Clinical HIV-1 eradication studies
Clinical HIV-1 eradication studies Mathias Lichterfeld, M. D., Ph. D. Massachusetts General Hospital Harvard Medical School No disclosures HIV-1 persistence despite HAART Blood Tissue HIV RNA (cps/ml)
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationIAS 2013 Towards an HIV Cure Symposium
Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T-cells Fiona Wightman Monash University, Melbourne, Australia
More informationHIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationMHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
More informationTargeting latent HIV infection: on the road towards an HIV Cure
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Targeting latent HIV infection: on the road towards an HIV Cure David M. Margolis, MD Professor of Medicine Treatment Cure Prevention Prevention
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationBRIEF REPORT METHODS. Twenty-seven HIV-infected individuals receiving ART for a median of 2 years were included in this study (Table 1).
BRIEF REPORT Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4 + T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy Jana Blazkova, 1,a
More informationNIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2012 September 1; 61(1): 19 22. doi:10.1097/qai.0b013e318264460f. Evaluation of HIV-1 Ambiguous Nucleotide
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationState of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationI declare that I have no financial conflicts of interest
I declare that I have no financial conflicts of interest Cytotoxic T-Lymphocytes Eliminate Defective HIV Proviruses Without Impacting Infectious Reservoirs R. Brad Jones Assistant Professor The George
More informationCTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence
IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationJournal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers
Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray
More informationPathogenesis Update Robert F. Siliciano, MD, PhD
Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationT Memory Stem Cells: A Long-term Reservoir for HIV-1
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal
IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal Marcus Altfeld Professor of Medicine Outline Immune recognition of HIV-1-infected cells Kinetics of antigen
More informationGLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW
GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW TOWARDS AN CURE PEOPLE FOCUSED SCIENCE DRIVEN JULY 2018 A GLOBAL STRATEGIC APPROACH TOWARDS
More informationInconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy
Letter to Editor (Annals of Oncology): Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy in cancer patients with HIV infection E. P. Scully 1,2,3, R. L. Rutishauser 4,
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationInvited Review CROI 2018: Advances in Basic Science Understanding of HIV
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationLow-Level Viremia in HIV
Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington
More informationDisulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 T Cell Model without Inducing Global T Cell Activation
JOURNAL OF VIROLOGY, June 2011, p. 6060 6064 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.02033-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Disulfiram Reactivates
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationHIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA
HIV-DNA: nuovo marcatore virologico Metodiche a confronto per la quantificazione di HIV-DNA Maria Carla Re Laboratorio Retrovirus e Agenti infettivi HIV correlati UO di Microbiologia, Università di Bologna
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationDestruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin
Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin J. Victor Garcia-Martinez, Ph.D. University of North Carolina, at Chapel Hill IAS 2013 Towards an HIV Cure Symposium Delivering
More informationScientific Rationale for Antiretroviral Therapy in 2005: Viral Reservoirs and Resistance Evolution
nternational AS Society USA Topics in H edicine Perspective Scientific Rationale for Antiretroviral Therapy in : iral Reservoirs and Resistance Evolution Hope for a cure for H- infection was dampened by
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationHuman Immunodeficiency Virus and Latency Reversing Agents A Path To Cure? Riti Rajendra Shah. Chapel Hill. December 2017
Human Immunodeficiency Virus and Latency Reversing Agents A Path To Cure? By Riti Rajendra Shah A Capstone Paper submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment
More informationDevelopment of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
Trejbalová et al. Clinical Epigenetics (2016) 8:19 DOI 10.1186/s13148-016-0185-6 RESEARCH Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationComparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies Susanne Eriksson 1., Erin H. Graf 2., Viktor Dahl 1., Matthew C. Strain 3., Steven A. Yukl 4,5., Elena S. Lysenko 2, Ronald
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationEffect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community of central Nigeria
Niger J Paed 2014; 41 (1): 1-6 Ebonyi AO Oguche S Dablets E Sumi B Yakubu E Sagay AS ORIGINAL Effect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community
More informationComparison of latent HIV-1 reactivation in multiple cell model systems
Comparison of latent HIV-1 reactivation in multiple cell model systems Celsa A. Spina, Jenny Anderson, Nancie M. Archin, Alberto Bosque, Jonathan Chan, Marylinda Famiglietti, Warner C. Greene, Angela Kashuba,
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationAP Biology. Viral diseases Polio. Chapter 18. Smallpox. Influenza: 1918 epidemic. Emerging viruses. A sense of size
Hepatitis Viral diseases Polio Chapter 18. Measles Viral Genetics Influenza: 1918 epidemic 30-40 million deaths world-wide Chicken pox Smallpox Eradicated in 1976 vaccinations ceased in 1980 at risk population?
More informationDiversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation
Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation By: Blake M. Hauser Senior Honors Thesis Department of Biology College of Arts and Sciences The University of North Carolina
More informationAdditional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T
September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationHIV/Sexual Health Clinical Education Session
HIV/Sexual Health Clinical Education Session http://courses.ashm.org.au/hiv/hiv-sexual-health-clinical-education-session/ About These Slide These slides may not be published, posted online, or used in
More informationComparison of HDAC inhibitors in clinical development
Human Vaccines & Immunotherapeutics ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: https://www.tandfonline.com/loi/khvi20 Comparison of HDAC inhibitors in clinical development Thomas Aagaard
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationInhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers
JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration
More informationSupporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
More informationRecent developments in the effort to cure HIV infection: going beyond N = 1
Recent developments in the effort to cure HIV infection: going beyond N = 1 Janet D. Siliciano, Robert F. Siliciano J Clin Invest. 2016;126(2):409-414. https://doi.org/10.1172/jci86047. Review Series Combination
More informationEx vivo analysis identifies effective HIV-1 latency reversing drug combinations
The Journal of Clinical Investigation Research article Ex vivo analysis identifies effective HIV-1 latency reversing drug combinations Gregory M. Laird, 1 C. Korin Bullen, 1 Daniel I.S. Rosenbloom, 2 Alyssa
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationDeterminants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice
DOI: 10.1111/hiv.12323 ORIGINAL RESEARCH Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice E McKinnon, 1, * A Castley, 2,3, * L
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationHIV-1 Eradication: Early Trials (and Tribulations)
Feature Review HIV-1 Eradication: Early Trials (and Tribulations) Adam M. Spivak 1 and Vicente Planelles 2, * Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with
More informationDefinitions of antiretroviral treatment failure for measuring quality outcomes
DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A
More informationMolecular Diagnosis Future Directions
Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationPredicting treatment outcomes using rich adherence data & antiretroviral pharmacometrics
Predicting treatment outcomes using rich adherence data & antiretroviral pharmacometrics Daniel Scholes Rosenbloom, Alison L. Hill, Robert F. Siliciano, Martin A. Nowak, Carol Golin, Robert Remien, Ira
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationIntermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Intermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption Joseph L. Yozviak DO,
More informationBeyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013
8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationHIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
More informationTherapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationAntiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationIt takes more than just a single target
It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationThe how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?
Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection
More informationTherapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
More informationHIV Eradication and the Quest for Functional Cure
HIV Eradication and the Quest for Functional Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures Consultant and/or research support
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More information